What Сиофор 1000 Treats: Main Uses and Benefits

This medication is commonly used as a starting oral treatment for Type 2 Diabetes Mellitus, especially in patients who are managing overweight or when diet and physical activity alone are insufficient to achieve desired control. It is an oral anti-hyperglycemic agent that is used to improve the overall control of blood glucose levels. It assists with managing the core symptom cluster of chronic hyperglycemia by stabilizing and helping to reduce elevated markers like Glycated Hemoglobin ( HbA1c). Indications for use generally include Type 2 Diabetes Mellitus, management of Prediabetes in high-risk individuals, and metabolic support for Polycystic Ovary Syndrome (PCOS).

---

Clinical Context: Metabolic Support This therapy may assist in managing the risk of long-term serious complications and may contribute to supporting a more regular menstrual cycle for women with PCOS.

The therapeutic domain includes insulin resistance. This therapeutic application is also relevant in managing the risk of progressing to full Type 2 Diabetes. It is generally used in contexts where additional symptomatic support is appropriate. It may assist patients who are also managing overweight or obesity, as it is generally associated with maintaining weight stability. For women with PCOS, this may contribute to supporting reproductive health.

Eligibility Map: Who Can and Cannot Use Сиофор 1000 — Official Regulatory Information

The eligibility profile for Сиофор 1000 (Metformin) is defined by official regulatory bodies, establishing strict contraindications based on critical organ function and acute physiological states.

Eligibility Scope	Official Regulatory Statement
Populations Allowed	Adults and adolescents mathbfge 10 years of age for Type 2 Diabetes Mellitus.
Populations Contraindicated
Severe Renal Impairment	Absolutely contraindicated if eGFR is below 30 mL/min/1.73 m^2 (per FDA/EMA).
Metabolic Status	Contraindicated in acute or chronic metabolic acidosis, including diabetic ketoacidosis.
Hypoxia/Organ Failure	Contraindicated in acute conditions that cause tissue hypoxia, such as unstable heart failure, respiratory failure, or recent myocardial infarction.
Hepatic/Alcohol Use	Contraindicated in patients with hepatic impairment (liver failure) and in cases of acute alcohol intoxication or alcoholism.

Age, Pregnancy, and Conditional Rules	Official Regulatory Statement
Age-Related Rules	Safety and effectiveness are not established in children under 10 years of age. Older adults (ge 65 years) require more frequent monitoring of renal function.
Conditional Use	Temporary discontinuation is required for major surgery under general anesthesia and for imaging procedures using iodinated contrast agents.
Pregnancy/Lactation	Use in pregnancy is generally not recommended (Insulin is the preferred agent). Use during lactation is not recommended as the medicine is excreted into human milk.

Connection to the overall eligibility profile: Regulatory documentation defines who can and cannot use the medicine by establishing absolute contraindications tied to critical organ function (renal and hepatic) and unstable acute conditions that pose a risk of metabolic crisis. Eligibility is strictly limited to stable patients who meet the approved age threshold and do not have conditions requiring temporary discontinuation.

Interactions with other medicines and products

The interaction profile for Metformin (Сиофор 1000) is predominantly defined by its mechanism of elimination and its influence on lactate metabolism, as documented in regulatory information.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substance / Class	Official Regulatory Outcome
Reduced Renal Clearance	OCT2/MATE Inhibitors (e.g., Cimetidine, Dolutegravir)	Leads to increased Metformin plasma concentration and accumulation.
Additive Risk	Insulin and Insulin Secretagogues	Increases the risk of hypoglycemia due to additive glucose-lowering effects.
Counteracting Effect	Agents with Hyperglycaemic Activity (e.g., Glucocorticoids, Thiazides)	May diminish the glucose-lowering effect, potentially resulting in a loss of glycemic control.

Procedural and Substance Restrictions

Excessive alcohol intake is formally restricted, as it potentiates the effect of Metformin on lactate, severely increasing the risk of lactic acidosis. This agent does not undergo hepatic metabolism and is therefore not associated with clinically significant Cytochrome P450 enzyme interactions.

Metformin must be temporarily discontinued at the time of or prior to procedures involving iodinated contrast media and certain surgical interventions. Following the procedure, therapy must be withheld for at least 48 hours and reinstituted only when stable renal function is confirmed. This mandated timing separation mitigates the risk of accumulation under compromised renal conditions.

How Сиофор 1000 Works

Сиофор 1000 (Metformin) influences core mechanisms involved in glucose homeostasis through specific actions on the liver and peripheral tissues. Its mechanism is defined by the activation of AMP-activated protein kinase ( AMPK), a central kinase involved in regulating cellular metabolism, without stimulating insulin release from the pancreas.

Central Inhibition of Glucose Production

Metformin involves the inhibition of Mitochondrial Complex I within hepatocytes. This action shifts the ATP: AMP ratio, leading to the activation of AMPK. The resulting cascade suppresses the activity of key gluconeogenic enzymes (like Glucose-6-phosphatase). This mechanism directly limits the liver’s overactive release of glucose into the systemic circulation, resulting in reduced hepatic glucose output.

Increasing Peripheral Glucose Responsiveness

In muscle and adipose cells, AMPK activation leads to the modulation and increased translocation of GLUT4 glucose transporters. This action increases the responsiveness of cells to existing insulin, promoting increased cellular uptake and utilization of circulating glucose, thereby influencing the rate of glucose clearance from the blood. The full functional output of the sensitizing mechanism is contingent upon the presence of some endogenous insulin.

The administration of Сиофор 1000 (Metformin Hydrochloride) follows established protocols for its oral use. The medicine is supplied as an oral, film-coated tablet and must be taken with meals (during or immediately after food) to align with guidelines for better tolerability.

Standard Dosing Regimens

Patient Group	Starting Dose	Maximum Daily Dose
Adults	500 mg twice daily or 850 mg once daily	2550 mg
Pediatric (Age 10+)	500 mg twice daily	2000 mg

Dose adjustment, known as titration, is a gradual process, typically increasing in increments of 500 mg weekly or 850 mg every two weeks based on clinical assessment. Total daily amounts exceeding 2000 mg are generally administered in three divided doses to enhance patient tolerance.

A critical procedural constraint is based on kidney function; use is contraindicated if the estimated Glomerular Filtration Rate (eGFR) is below 30 mL/min/1.73 m^2. Furthermore, initiation is not recommended when the eGFR falls between 30 and 45 mL/min/1.73 m^2. If a scheduled dose is missed, it must not be doubled; the individual should simply resume the next scheduled dose at the correct time.

Research evidence / Overview of Studies for Сиофор 1000

The research base for Сиофор 1000, which contains Metformin, is primarily derived from large-scale, long-running clinical trials and observational studies that have helped establish the clinical situations it was studied for. These studies included long-term follow-up periods and involved thousands of participants. Findings describe group patterns related to how the medicine was observed to affect various health markers and long-term event rates.

---

Evidence for Use in Type 2 Diabetes Mellitus

Research exploring the use of this medicine as an initial treatment for Type 2 Diabetes Mellitus (T2DM) was studied for in foundational, large-scale Randomized Controlled Trials (RCTs). Researchers examined glycemic markers such as HbA1c and tracked the occurrence of major vascular events. Studies reported sustained measurements of glycemic markers across the follow-up period. Post-trial monitoring that extended for decades described patterns related to the occurrence of diabetes-related death and myocardial infarction (heart attack). The reported patterns regarding clinical endpoints were associated with a specific overweight subgroup within the foundational RCTs.

The evidence base for long-term clinical outcomes in the entire T2DM population, as distinct from the specific overweight subset, is an ongoing topic of scientific inquiry. Additionally, comparative evidence is lacking regarding direct, head-to-head long-term outcomes against the newer classes of diabetes medications that have become available in recent decades.

---

Evidence for Use in Prediabetes and High-Risk Groups

Research examined the use of this medicine in high-risk individuals with Prediabetes, specifically in landmark RCTs. The primary focus of this research was to examine the time until the development of confirmed Type 2 Diabetes. The initial trials reported patterns related to the incidence rate of T2DM over the short- to medium-term follow-up period in the studied high-risk groups. The primary analysis of the initial trials described that the intensive lifestyle intervention cohort demonstrated a more noticeable pattern in reducing the incidence of T2DM compared to the medicine cohort.

What remains uncertain is the medicine’s specific effect on long-term cardiovascular complications in this population. As participants who developed T2DM began taking other medications over time, the isolation of the medicine’s durable effect on these later complications appears to be challenging.

---

Research Gaps and Areas of Uncertainty

For the PCOS population, the evidence quality varies across studies, and certainty remains low for long-term outcomes. Subgroup findings are uncertain in some meta-analyses, meaning that results apply only to the populations studied in the original trials, and data for certain comorbid conditions remain insufficient. Findings describe group patterns, and research provides context but not individual predictions.

Key Studies & References Long-term complications in youth-onset type 2 diabetes (TODAY Study Group and TODAY2 Follow-up)

Common questions about Сиофор 1000 (FAQ)

---

Q: Is Siofor 1000 insulin?

A: Siofor 1000 contains the active substance metformin, which belongs to a class of medicines called biguanides. Official descriptions state that the medicine works to reduce blood glucose levels without stimulating the pancreas to release more insulin. Therefore, it is not an insulin product.

---

Q: Are Siofor 1000 and Glucophage the same?

A: Siofor 1000 is a commercially known brand name for the medicine containing the active substance metformin hydrochloride. Glucophage is also a well-known brand name for the same active substance. Brand names can differ regionally, but they share the same primary active ingredient.

---

Q: Why do doctors often prescribe Siofor 1000?

A: It is described in official documents as a first-line therapy, meaning it is often the initial drug examined for use in managing Type 2 Diabetes Mellitus. It is generally described as being examined for use when blood sugar control remains insufficient through diet and exercise alone.

---

Q: How long until Siofor 1000 starts to work?

A: Its full effect takes time to establish. Regulatory procedures often involve reviewing the drug's effect and potentially adjusting the dosage over periods of 10 to 15 days to find an optimal stable concentration.

---

Q: What to do if I missed a dose of Siofor 1000?

A: If a dose is missed, regulatory procedure states that the individual should not take a double dose to compensate. The individual should simply resume the next scheduled dose at the correct time.

---

Q: What happens if I suddenly stop taking Siofor 1000?

A: The cessation of treatment is typically associated with a loss of the medicine's glucose-lowering influence. This may lead to the return of previous elevated blood sugar levels (hyperglycemia).

---

Q: What is the maximum duration for taking Siofor 1000?

A: The medicine is approved and described for the long-term, chronic management of Type 2 Diabetes. There is no predetermined maximum duration listed in regulatory documentation for its continued use, provided that the required monitoring and assessments are performed.

---

Q: Why must Siofor 1000 be taken with meals?

A: Official administration guidelines recommend taking the tablet during or immediately after food. This procedural measure is advised to help reduce the incidence of common gastrointestinal side effects, such as nausea, vomiting, or diarrhea, thereby improving overall tolerability.

---

Q: Can Siofor 1000 cause a metallic taste in the mouth?

A: Yes, official safety profiles list a taste disturbance, which is frequently described as a metallic taste, as a Common side effect. This means it may affect up to 1 in 10 people taking the medicine.

---

Q: What are the signs of Siofor 1000 overdose?

A: The most significant risk associated with overdose is a severe metabolic complication called lactic acidosis. Symptoms described in regulatory text include severe muscle pain or cramps, abdominal discomfort, difficulty breathing, and profound fatigue, all of which require immediate medical attention.

---

Q: What is the difference between Siofor 500, 850, and 1000?

A: The numbers 500, 850, and 1000 in the name refer specifically to the milligram ( mg) strength of the active ingredient, metformin hydrochloride, contained within each tablet. The strength of the tablet is determined by the prescriber.

---

Q: Should Siofor 1000 be cancelled for infectious diseases?

A: The drug is contraindicated in acute conditions that could cause tissue hypoxia (a lack of oxygen) or severe dehydration. This includes severe infections or acute illnesses accompanied by continuous vomiting or diarrhea. Temporary discontinuation may be required in such circumstances.

---

Q: Can the Siofor 1000 tablet be split?

A: The Siofor 1000 tablet is typically manufactured as a scored tablet, meaning it has a visible break-line across the surface. The presence of a break-line indicates the tablet is designed for division.

---

Q: Can Siofor 1000 cause an allergic reaction?

A: Official safety documents list Very Rare skin reactions such as hives (urticaria), rash (erythema), and itching (pruritus). These types of reactions are consistent with hypersensitivity or allergic responses, though they occur infrequently.

---

Q: Is it possible to develop an addiction to Siofor 1000?

A: Siofor 1000 is classified as an oral medicine for lowering high blood sugar, and it is not categorized as a controlled substance. Official documents do not list addiction or physical dependency as a known risk or side effect of the medicine.

---

Q: Can Siofor 1000 cause hypoglycemia?

A: When Siofor 1000 is used alone (as monotherapy), official labeling states that it does not typically cause low blood sugar (hypoglycemia). The risk increases significantly when taken with other diabetes medicines that actively lower blood sugar.

---

Q: What vitamins might be needed with long-term use of Siofor 1000?

A: Long-term exposure to the medicine is officially associated with the potential for decreased Vitamin B12 absorption. Official documents advise that Vitamin B12 levels may require monitoring, particularly in individuals with pre-existing risk factors, due to the potential association with megaloblastic anaemia over time.

---

Q: Why do some people experience fatigue when taking Siofor 1000?

A: Although general fatigue is not a primary common side effect, official documents note that severe weakness or tiredness is a non-specific symptom associated with Vitamin B12 deficiency, a potential effect of long-term exposure, and lactic acidosis (a rare complication).

---

Q: Does Siofor 1000 have delayed side effects?

A: The safety profile explicitly notes that decreased Vitamin B12 absorption is a consequence of long-term exposure, rather than an immediate reaction. This potential effect, which can lead to megaloblastic anaemia over time, represents a condition that develops later in treatment.

---

Q: How does Siofor 1000 affect appetite?

A: Official safety documents list loss of appetite (anorexia) as a Very Common side effect, meaning it may affect more than 1 in 10 people. This disturbance is typically reported when treatment is first started or when the dose is increased.

---

Q: Does Siofor 1000 help with prediabetes?

A: Research evidence has been published based on clinical trials that examined the use of this medicine in high-risk groups diagnosed with Prediabetes. The findings indicated patterns where the incidence of Type 2 Diabetes was observed to be lower in the studied high-risk populations taking the medicine compared to placebo.

---

Q: Can alcohol be consumed during treatment with Siofor 1000?

A: Regulatory warnings state that alcohol use, especially when excessive, is associated with a greater risk of lactic acidosis. This risk is notably higher when combined with fasting, malnutrition, or hepatic impairment.

---

Q: Is there research on the long-term safety of Siofor 1000?

A: Yes, the research foundation for the active ingredient, metformin, includes large-scale, long-running clinical trials and observational studies. These investigations have allowed researchers to examine long-term patterns and outcomes associated with the medicine over many years.

---

Q: Can Siofor 1000 be taken if there are heart problems?

A: The medicine is strictly contraindicated (must not be used) in acute conditions that cause tissue hypoxia (a lack of oxygen). The contraindications are tied to acute conditions that disrupt oxygen supply, such as unstable heart failure or acute myocardial infarction, which require temporary or permanent discontinuation.

---

Q: Does Siofor 1000 affect cholesterol levels?

A: While the primary action of the medicine is related to glucose control, research evidence has indicated that it is generally associated with a neutral or modest positive influence on lipid markers, including cholesterol and triglycerides, as part of its overall metabolic effect.

---

Q: Is Siofor 1000 used for Polycystic Ovary Syndrome?

A: Official documentation notes that research has examined the medicine’s use in the PCOS population. However, the available data for long-term outcomes in this group is generally described as varying across studies, and certainty remains low.

---

Q: Is Siofor 1000 a prolonged-release tablet?

A: Siofor 1000 is officially described as a film-coated tablet, which is typically an immediate-release formulation. Products specifically designed for prolonged or extended release ( XR) are separate formulations with different designs.

Official Storage and Disposal Requirements

Storage and handling instructions for Siofor 1000 (Metformin) are based strictly on regulatory labeling to maintain product stability and ensure environmental safety.

Storage Conditions

Requirement	Official Regulatory Statement
Temperature	No special temperature storage conditions are required (Ambient/Room Temperature).
Protection	Must be stored in the original package to protect from light and moisture to preserve integrity.
Child Safety	Must be kept out of the reach and sight of children.

Disposal Instructions

Regulatory documents specify that unused or expired Siofor 1000 tablets must not be disposed of in household trash or poured into wastewater, as these measures help to protect the environment. Disposal should be carried out in accordance with local requirements, typically by returning the product to a pharmacist or designated collection point.